NCT01306578

Brief Summary

Comparing whether intravenous immune globulin or plasma exchange is superior in treating mechanically ventilated children with Guillain Barre syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2007

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2010

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

March 1, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 2, 2011

Completed
Last Updated

March 2, 2011

Status Verified

February 1, 2011

Enrollment Period

2.9 years

First QC Date

March 1, 2011

Last Update Submit

March 1, 2011

Conditions

Keywords

Guillain Barre syndromeIVIGPlasma exchange

Outcome Measures

Primary Outcomes (1)

  • Duration of mechanical ventilation

    How many days did the mechanical ventilation continue

    21 days (average)

Secondary Outcomes (2)

  • PICU stay

    28 days (average)

  • Ability to walk

    4 weeks from PICU discharge

Study Arms (2)

IVIG group

ACTIVE COMPARATOR

20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day

Drug: IVIG

Plasma Exchange

ACTIVE COMPARATOR

21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days

Procedure: Plasma Exchange

Interventions

IVIGDRUG

Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days

Also known as: Sandglobin
IVIG group

Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days

Also known as: Plasmapheresis
Plasma Exchange

Eligibility Criteria

Age1 Month - 18 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age: children from 1 month - 18 years old
  • Clinical diagnosis of Guillain Barre syndrome
  • Requirement of mechanical ventilation

You may not qualify if:

  • Need for mechanical ventilation beyond 14 days from disease onset
  • Child receiving IVIG or PE prior to enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura University Children Hospital

Al Mansurah, Dakahlia Governorate, Egypt

Location

Related Publications (2)

  • Saleh M, Boukhdoud M, Boukhdoud H, Al Zein M, Salameh P. Landscape of Guillain-Barre Syndrome Interventional Clinical Trials. J Clin Neuromuscul Dis. 2023 Mar 1;24(3):119-129. doi: 10.1097/CND.0000000000000441.

  • El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barre syndrome: a randomized study. Crit Care. 2011 Jul 11;15(4):R164. doi: 10.1186/cc10305.

MeSH Terms

Conditions

Guillain-Barre Syndrome

Interventions

Immunoglobulins, IntravenousPlasma ExchangePlasmapheresis

Condition Hierarchy (Ancestors)

PolyradiculoneuropathyAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesPolyneuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesAutoimmune DiseasesImmune System DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Immunoglobulin GImmunoglobulin IsotypesAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulinsBlood TransfusionBiological TherapyTherapeuticsBlood Component RemovalSorption DetoxificationExtracorporeal CirculationSurgical Procedures, Operative

Study Officials

  • Mohammed A El-Bayoumi, MD, FRCPCH

    Head of PICU, Mansoura University Children Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 1, 2011

First Posted

March 2, 2011

Study Start

January 1, 2007

Primary Completion

December 1, 2009

Study Completion

February 1, 2010

Last Updated

March 2, 2011

Record last verified: 2011-02

Locations